Urothelial Carcinoma Clinical Trials
Urothelial Carcinoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for urothelial Carcinoma. Corterve aggregates actively recruiting Urothelial Carcinoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Urothelial Carcinoma studies
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialNCT06770582PHASE2National Cancer Institute (NCI)Non-Muscle Invasive Bladder Urothelial CarcinomaTucson, Arizona
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerNCT04628767PHASE2, PHASE3National Cancer Institute (NCI)Renal Pelvis and Ureter Urothelial CarcinomaKingman, Arizona
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsNCT06293898PHASE1SystImmune Inc.Endometrial CancerBirmingham, Alabama
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382PHASE2National Cancer Institute (NCI)Bladder AdenocarcinomaBirmingham, Alabama
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyNCT05987241PHASE2, PHASE3National Cancer Institute (NCI)Muscle Invasive Bladder Urothelial CarcinomaPhoenix, Arizona
- Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial CarcinomaNCT07048457PHASE2Yale UniversityLocally Advanced Urothelial CarcinomaNew Haven, Connecticut
- A Study of GEN1106 in Participants With Solid TumorsNCT07416123PHASE1GenmabSolid TumorsNew Haven, Connecticut
- Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerNCT07421700PHASE1, PHASE2PfizerUrothelial CancerFayetteville, Arkansas
- Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary TractNCT07789119M.D. Anderson Cancer CenterUrothelial CarcinomaHouston, Texas
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerNCT06503614PHASE2John SfakianosNon-muscle Invasive Bladder CancerSan Francisco, California
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerNCT06524544PHASE3National Cancer Institute (NCI)Locally Advanced Urothelial CarcinomaPhoenix, Arizona
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramNCT06265285PHASE2Mayo ClinicAdvanced Esophageal Squamous Cell CarcinomaJacksonville, Florida
Urothelial Carcinoma trials by state
Urothelial Carcinoma trials by metro
Frequently asked questions
- How do I find recruiting Urothelial Carcinoma clinical trials?
- Browse the actively recruiting Urothelial Carcinoma studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Urothelial Carcinoma clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Urothelial Carcinoma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.